clinical trials

AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma
AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma
Marketwatch
AbbVie
venetoclax
Multiple Myeloma
FDA
clinical trials
Flag link:
Dermira shares double on positive eczema data
Dermira shares double on positive eczema data
Biopharma Dive
Dermira
lebrikizumab
clinical trials
eczema
Flag link:
Allergy Therapeutics suffers phase 3 birch allergy jab trial failure
Allergy Therapeutics suffers phase 3 birch allergy jab trial failure
Pharmaforum
Allergy Therapeutics
clinical trials
birch allergy
B301
allergy shots
Flag link:
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study
Yahoo/Zacks.com
Lexicon Pharmaceuticals
clinical trials
Xermelo
biliary tract cancer
Flag link:
American College of Cardiology Conference Roundup - day 1
American College of Cardiology Conference Roundup - day 1
CP Wire
American College of Cardiology
Novartis
Entresto
heart failure
Edwards Lifesciences
Apple
TAVR
wearables
clinical trials
Apple Watch
atrial fibrillation
Flag link:
American College of Cardiology Conference Roundup - day 1
American College of Cardiology
Novartis
Entresto
heart failure
Edwards Lifesciences
Apple
TAVR
wearables
clinical trials
Apple Watch
atrial fibrillation
Flag link:
Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
Investors Business Daily
Amgen
Repatha
clinical trials
Flag link:
Gottlieb pushes out more guidances on modernizing trials
Gottlieb pushes out more guidances on modernizing trials
BioCentury
FDA
Scott Gottlieb
clinical trials
Flag link:
Celgene’s Abraxane Fails to Hit the Mark in a Phase III Pancreatic Cancer Study
Celgene’s Abraxane Fails to Hit the Mark in a Phase III Pancreatic Cancer Study
BioSpace
Celgene
Abraxane
clinical trials
pancreatic cancer
Flag link:
FDA looks to broaden cancer trial eligibility
FDA looks to broaden cancer trial eligibility
BioCentury
FDA
cancer
clinical trials
oncology
Flag link:
Lilly's combo treatment meets main goal in lung cancer late-stage study
Lilly's combo treatment meets main goal in lung cancer late-stage study
Yahoo/Reuters
Eli Lilly
Cyramza
clinical trials
metastatic non-small cell lung cancer
Roche
erlotinib
Flag link:
FDA Rescinds Two Breakthrough Therapy Designations
FDA Rescinds Two Breakthrough Therapy Designations
RAPS.org
FDA
breakthrough therapies
clinical trials
Tonix Pharmaceuticals
Tonmya
Trevena
oliceridine
Flag link:
Gilead shares early clinical data on HIV capsid inhibitor
Gilead shares early clinical data on HIV capsid inhibitor
Fierce Biotech
Gilead Sciences
HIV
GS-6207
clinical trials
Flag link:
Briggs Morrison’s little biotech Syndax concedes 2 key trial setbacks for its lead drug, as shares shrivel some more
Briggs Morrison’s little biotech Syndax concedes 2 key trial setbacks for its lead drug, as shares shrivel some more
Endpoints
Syndax
Briggs Morrison
clinical trials
entinostat
Flag link:
‘Brutal disaster.’ Allergan’s would-be antidepressant fails patients in four studies
‘Brutal disaster.’ Allergan’s would-be antidepressant fails patients in four studies
Stat
Allergan
antidepressants
repastinel
clinical trials
Flag link:
Gilead scores key HIV data as Descovy proves non-inferior to Truvada
Gilead scores key HIV data as Descovy proves non-inferior to Truvada
BioPharma Dive
Gilead Sciences
HIV
Descovy
Truvada
clinical trials
Flag link:
Vertex Faces Choice After Second CF Drug Combo Succeeds in Phase 3
Vertex Faces Choice After Second CF Drug Combo Succeeds in Phase 3
Xconomy
Vertex Pharmaceuticals
cystic fibrosis
clinical trials
VX-445
Symdeko
Flag link:
Ascendis jumps on Phase III readout for once-weekly growth hormone
Ascendis jumps on Phase III readout for once-weekly growth hormone
BioCentury
Ascendis
TransCon hGH
pediatric growth hormone deficiency
clinical trials
Flag link:
After nebulizer flop, Verona touts interim PhII results on another version of its lead COPD drug
After nebulizer flop, Verona touts interim PhII results on another version of its lead COPD drug
Endpoints
Verona
clinical trials
ensifentrine
COPD
Flag link:
Can Novavax Convince the FDA Its Vaccine Deserves a Chance?
Can Novavax Convince the FDA Its Vaccine Deserves a Chance?
Motley Fool
Novavax
RSV
vaccines
FDA
clinical trials
Flag link:

Pages